<DOC>
	<DOCNO>NCT02222922</DOCNO>
	<brief_summary>To assess safety tolerability increase dose level PF-06647020 patient advance solid tumor order determine maximum tolerate dose select recommend Phase 2 dose .</brief_summary>
	<brief_title>A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Diagnosis solid tumor advanced/metastatic resistant standard therapy standard therapy available Performance Status 0 1 Adequate bone marrow , kidney , liver function Part 2 include ovarian cancer , target express triple negative breast cancer non small cell lung cancer patient OVCA pt must progress receive within 6mos completion least 4 cycle platinumcontaining regimen . Prior line therapy 3 regimen . OVCA pt exclude follow : nonepithelial , inlcuding malignant mixed mullerian tumor , prior radiotherapy pelvis/abdomen , pt CA125 disease , unresolved bowel obstruction , include subocclusive disease , related underlying disdease history abdominal fistula , GI perforation itraabdominal abscess . Brain metastases require steroid Drugdrug interaction include advanced metastatic breast cancer , ovarian cancer , non small cell lung cancer patient Major surgery , radiation therapy , systemic anticancer therapy within 4 week study treatment start Active clinically significant bacterial , fungal , viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ADC</keyword>
	<keyword>PF-06647020</keyword>
	<keyword>solid tumor</keyword>
	<keyword>tumor</keyword>
	<keyword>neoplasm metastasis</keyword>
	<keyword>TNBC</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>advanced metastatic breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>OVCA</keyword>
</DOC>